Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

PAncreatic Cancer therapeutic discovery using Monoclonal ANtibodies

Project description

Pioneering pancreatic cancer treatment leveraging monoclonal antibodies

Pancreatic ductal adenocarcinoma (PDAC), a type of pancreatic cancer that begins in the cells lining the ducts of the pancreas, accounts for more than 80 % of pancreatic cancers. Treatment options are limited and minimally effective, making it one of the most lethal diseases. PDAC is associated with an overexpression of a cell surface protein that leads to tumour proliferation, invasion, and migration. The ERC-funded PACMAN project aims to provide preclinical proof of concept of treating PDAC with monoclonal antibodies targeting the protein. It will leverage patient-derived PDAC models to investigate therapeutic efficacy and biomarkers associated with treatment response. Success could pave the way for a treatment for this aggressive and deadly disease.

Objective

The PACMAN project aims to develop a novel therapeutic approach for treating pancreatic ductal adenocarcinomas (PDAC), one of the deadliest cancers with limited therapeutic options. The project focuses on targeting an overexpressed cell surface protein in PDAC implicated in tumor proliferation, invasion and migration by driving carcinogenic signaling. This study aims to investigate the ability of a highly specific monoclonal antibody targeting this protein to treat PDAC. By studying the therapeutic efficacy and unravelling associated biomarkers of treatment response in patient-derived PDAC models, the PACMAN program will provide preclinical proof of concept to treat PDAC with a novel class of monoclonal antibodies. Based on a robust patient-derived data package, this innovative approach provides the perspective for a first-in-class therapy for PDAC, addressing a critical unmet medical need and offering new hope for patients with this aggressive cancer.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-POC

See all projects funded under this call

Host institution

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Net EU contribution
€ 150 000,00
Address
RUE DE TOLBIAC 101
75654 Paris
France
Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (1)